(Q37118473)

18 August 2017

1 reference

title

Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal (English)

1 reference

polycystic ovary syndrome

18 August 2017

main subject

1 reference

1 reference

1 reference

1 reference

Andrea Dunaif

1

1 reference

18 August 2017

publication date

25 March 2008

1 reference

Nature Clinical Practice Endocrinology and Metabolism

18 August 2017

published in

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

272-283

1 reference

Polycystic ovary syndrome

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The polycystic ovary. I. Clinical and histologic features

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Polycystic ovary syndrome: syndrome XX?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Obesity, metabolic syndrome, and coronary atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Polycystic ovary syndrome and cardiovascular disease: a premature association?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Polycystic ovaries--a common finding in normal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

1 reference

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

1 reference

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metformin has direct effects on human ovarian steroidogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Does metformin modify ovarian responsiveness during exogenous FSH ovulation induction in normogonadotrophic anovulation? A placebo-controlled double-blind assessment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine inseminatio

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The use of metformin for women with PCOS undergoing IVF treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Management of infertility

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Obesity and reproductive disorders: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Body mass and probability of pregnancy during assisted reproduction treatment: retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Should we continue or stop insulin sensitizing drugs during pregnancy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughou

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Oral hypoglycaemic agents in 118 diabetic pregnancies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

A trial in progress: gestational diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial)

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Metformin administration improves endothelial function in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The DREAM trial – Authors' reply

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Rosiglitazone and cardiotoxicity--weighing the evidence

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

The role of lifestyle modification in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Polycystic ovary syndrome and endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0787

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0787

1 reference

Dimensions Publication ID

18 August 2017

1026616885

0 references

Fatcat ID

release_hku5zunybvhbfmo3bk2wzu4uju

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hku5zunybvhbfmo3bk2wzu4uju

24 November 2022

mapped directly with Wikidata item

1 reference